Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Strategic deal to advance mature medicines globally
Original title: “Sanofi and Cheplapharm forge new medicines partnership”
New GLP-1 therapy indications mean new challenges for pharma companies, from care to consumer trust.
Original title: “Are healthcare systems really ready for GLP-1s?”
As oncology care grows personalized and home-based, support around treatment becomes as vital as treatment.
Original title: “Behind the outcomes: How whole-patient support is reshaping oncology care”
In May 2023, Worldwide Clinical Trials partnered with Every Cure to accelerate the identification and advancement of therapies for rare disease patients. The collaboration combines drug repurposing strategies, artificial intelligence-driven data analytics, and clinical research support to improve treatment ... In May 2023, Worldwide Clinical Trials partnered with Every Cure to accelerate the identification and advancement of therapies for rare disease patients. The collaboration combines drug repurposing strategies, artificial intelligence-driven data analytics, and clinical research support to improve treatment development and trial efficiency. The integration of real-world evidence into clinical validation is expected to further strengthen trial design, regulatory submissions, and post-market research. The expansion of gene and cell therapy pipelines is a major factor driving demand for rare disease CRO services. Rare disease CROs support sponsors by designing and managing clinical trials, recruiting patients with specific genetic conditions, coordinating global research sites, maintaining regulatory compliance, and handling complex clinical data. Investment in cell and gene therapies continues to increase. Markets Covered: 1) By Service Type: Drug Development Strategy; Clinical Trial Management; Patient Recruitment and Retention Services; Data Management and Biostatistics; Regulatory Affairs and Consulting; Pharmacovigilance Services; Medical Writing and Documentation; Decentralized Clinical Trial Services; Other Service Types 2) By Phase: Pre Clinical; Phase One; Phase Two; Phase Three; Phase Four 3) By Therapeutic Area: Oncology; Neurology; Cardiovascular Disorders; Metabolic Disorders; Genetic Disorders; Hematology; Immunology; Rare Infectious Diseases; Other Rare Indications 4) By Delivery M
Original title: “Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook”
As molecule complexity rises, advanced cell line development platforms are giving biopharma companies new tools to overcome expression challenges, improve stability and reach the clinic faster.
Original title: “Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers”
A new five-year biotech plan has been released by the Chinese government, revealing ambitious goals such as achieving five blockbuster medicines on the global markets in that time.
Original title: “China plans to transform $3M biotech sector into $522B powerhouse by 2030”
The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.
Original title: “Xenon shares fall following depression trial pause”